ストックスクリーナーアプリを入手
22.62
6.70%
1.42
アフターアワーズ：
22.54
-0.08
-0.35%
Summit Therapeutics Inc (SMMT) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.SMMT - FinancialContent
Summit Therapeutics Holds Successful 2025 Annual Meeting - TipRanks
Summit Therapeutics SMMT Sees Institutional Growth on Nasdaq Composite - Kalkine Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - GlobeNewswire Inc.
Summit Therapeutics (NASDAQ:SMMT) Upgraded at Leerink Partnrs - MarketBeat
Summit Therapeutics (SMMT) Stock Drops After Analyst's Downgrade - GuruFocus
Kalkine : Summit Therapeutics Slides as Nasdaq Index Remains Largely Steady - Kalkine Media
Summit Therapeutics (SMMT) Receives Underperform Rating from Lee - GuruFocus
Why Summit Therapeutics Stock Tanked Today - Barchart.com
U.S. Markets Closed Mixed Wednesday As SailPoint Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Faces Analytical Downgrade on Drug Prospects - GuruFocus
Merck rival Summit draws a rare sell-equivalent rating - Seeking Alpha
Summit Therapeutics (SMMT) Receives New Analyst Coverage from Leerink Partners | SMMT Stock News - GuruFocus
Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target - marketscreener.com
Summit Therapeutics at Goldman Sachs Healthcare Conference: Strategic Advances in Cancer Treatment - Investing.com Canada
Transcript : Summit Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 01 - MarketScreener
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape - MSN
Why is Summit stock in selloff after late-stage trial data for lead asset? - MSN
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday - MSN
Wellington Management Group LLP Sells 4,069 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Brokerages Set Summit Therapeutics Inc. (NASDAQ:SMMT) Target Price at $37.40 - Defense World
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire
Summit Therapeutics Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SMMT Stock News - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brown-Forman Corporation - GlobeNewswire Inc.
Summit Therapeutics Expands Team with $1.2M Stock Options Package for 7 New Hires - Stock Titan
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial - MSN
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | SMMT Stock News - GuruFocus
Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Yahoo Finance
2 Soaring Stocks Wth More Upside Potential - AOL.com
Ameriprise Financial Inc. Acquires New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns "Market Outperform" Rating from JMP Securities - MarketBeat
Investors Are Dumping These 10 Stocks - Insider Monkey
Why Summit Therapeutics Inc. (SMMT) Crashed Last Week - MSN
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday - MSN
Summit Therapeutics: What's This Ivonescimab Rollercoaster - Nasdaq
10 Stocks Leaving Wall Street in The Dust - Insider Monkey
Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer (NASDAQ:SMMT) - Seeking Alpha
Down 36.7% in 4 Weeks, Here's Why Summit Therapeutics (SMMT) Looks Ripe for a Turnaround - Yahoo Finance
Summit Therapeutics: Market Overreaction Creates Opportunity (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results - sharewise
Summit Therapeutics (SMMT) Gains Attention Following Positive Ph - GuruFocus
Summit Therapeutics (SMMT) Gains Attention Following Positive Phase III Trial Results | SMMT Stock News - GuruFocus
SMMT: Summit Therapeutics' Market Outperform Rating Reiterated by JMP Securities | SMMT Stock News - GuruFocus
0.64%
1.45%
大文字化:
|
ボリューム (24 時間):